J Korean Diabetes Assoc.
2007 Jul;31(4):297-301. 10.4093/jkda.2007.31.4.297.
Peroxisome Proliferator Activated Receptor-delta (PPAR-delta)
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine.
- KMID: 2222516
- DOI: http://doi.org/10.4093/jkda.2007.31.4.297
Abstract
- The development of novel treatments for the metabolic syndrome is imminent for decreasing the prevalence of type 2 diabetes and cardiovascular disease. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor super-family of ligand-induced transcription factors. Among them, PPAR-alpha and PPAR-gamma are therapeutic targets for dyslipidemia and insulin resistance. Recent studies have uncovered a dual benefit of PPAR-delta for both dyslipidemia and insulin resistance. Furthermore, PPAR-delta enhances fatty acid oxidation and energy uncoupling in adipose tissue and muscle. PPAR-delta activation seems to operate similarly to the caloric restriction and prolonged exercise. Combined effects of PPAR-delta make it a promising therapeutic target for the metabolic syndrome, and ongoing studies about PPAR-delta will improve our knowledge of the physiologic regulation of whole body energy metabolism.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Current Understanding of Peroxisome Proliferator-Activated Receptor delta
- Effects of Peroxisome Proliferator-Activated Receptor (PPAR) Delta on the Growth and Invasion of a Thyroid Cancer Cell Line
- An Activation of Peroxisome Proliferator-Activated Receptor delta Attenuate Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease in Rats
- The Peroxisome Proliferator-Activated Receptor delta Agonist, GW501516, Inhibits Angiogenesis through Dephosphorylation of Endothelial Nitric Oxide Synthase
- Refocusing Peroxisome Proliferator Activated Receptor-alpha: A New Insight for Therapeutic Roles in Diabetes
